NCT03770637已完成2 期
A Phase 2, Interventional, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Glucagon RTU in Subjects Who Experience Hyperinsulinemic Hypoglycemia After Bariatric Surgery
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 5
- 主要终点
- Blood glucose recovery: Out-patient
研究概览
简要总结
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a subject's last dose of study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
The sponsor, investigators/staff and subjects will be blinded to treatment assignment. Active study drug and placebo have the identical appearance (i.e., clear, colorless liquid), and both will be provided in identical vials with blinded labeling that does not reveal the contents of the vial.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Aged 18 to 75 years of age, inclusive
- •Symptoms of hypoglycemia that developed after bariatric surgery (Roux-en-Y gastric bypass [RYGB] only) in the absence of antidiabetic medications
- •History of bariatric surgery (RYGB only), at least 6 months prior to screening
- •Whipple's triad
- •Ability to both experience and recognize hypoglycemic awareness.
- •Documented glucose levels < 54 mg/dL when experiencing symptoms suggestive of hypoglycemia
- •Relief of hypoglycemia symptoms when the glucose is raised to normal
- •Diagnosis of post-bariatric hypoglycemia (PBH) by a physician, requiring intervention such as intake of oral carbohydrates. This diagnosis includes documentation of endogenous hyperinsulinism in the presence of low plasma glucose.
- •In subjects with medical history of diabetes, medical documentation of postoperative remission of diabetes mellitus (fasting glucose < 110 mg/dL), and HbA1c < 6% (or 42 mmol/mL) with all previous antidiabetic medication discontinued for at least 6 months before screening.
- •Body mass index (BMI) ≤ 40 kg/m2
- •Willingness to follow all study procedures, including attending all clinic visits and self-administering blinded study drug at home for 12 weeks
- •Understands the study procedures, alternative treatment available, and risks involved with the study, and he/she voluntarily agrees to participate by giving written informed consent
- •Women of childbearing potential must have a negative urine pregnancy test and agree to use contraception and refrain from breast-feeding during the study and for at least 15 days after participating in the study.
排除标准
- •Documented hypoglycemia occurring in the fasting state (> 12 hours fast) within 12 months of study entry
- •Hypoglycemic unawareness as evidenced by a Gold Scale score > 4 at screening
- •Early Dumping Syndrome
- •Known insulinoma or adrenal insufficiency
- •Active treatment with any insulin/insulin secretagogues, or other diabetes medications except for acarbose and glucagon-like peptide 1 (GLP-1) analogues
- •Chronic kidney disease Stage 4 or 5 or an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m2 at screening
- •Hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase ≥ 3 times the upper limit of normal (ULN); hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL
- •Congestive heart failure, New York Heart Association Class III or IV
- •History of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening.
- •History of a cerebrovascular accident within 6 months prior to screening or with major neurological deficits
- •Seizure disorder (other than with suspected or documented hypoglycemia).
- •Active malignancy, except for basal or squamous cell skin cancers
- •Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)
- •Major surgical operation within 30 days prior to screening
- •Hematocrit ≤ 30%
- •Bleeding disorder, treatment with warfarin, or platelet count < 50,000 /mm3
- •Active alcohol abuse or substance abuse (per investigator assessment)
- •Current chronic administration of oral or parenteral corticosteroids, however topical, intraarticular, and inhaled corticosteroids are allowed
- •Use of an investigational drug within 15 days or 5 half-lives, whichever is longer, prior to screening
- •Member of a special vulnerable populations such as pregnant women, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable
- •Any other medical condition or finding that in the opinion of the investigator or sponsor, would compromise the safety of the subject or compromise the integrity of the study data
研究组 & 干预措施
Glucagon RTU (glucagon injection)
Experimental
Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
干预措施: Glucagon RTU (Drug)
Placebo
Placebo Comparator
Non-active vehicle for Glucagon RTU; 60 μL injection
干预措施: Placebo (Other)
结局指标
主要结局
Blood glucose recovery: Out-patient
时间窗: At 15 minutes following administration of study drug
Frequency of blood glucose \> 70 mg/dL
Blood glucose recovery: CRC
时间窗: At 15 minutes following administration of study drug
Number of subjects with blood glucose \> 70 mg/dL
次要结局
- Symptomatic Recovery: CRC(At 15, 30, and 60 minutes following administration of study drug)
- Incidence of severe hypoglycemia: Out-patient(During 12 weeks of out-patient treatment)
- Incidence of severe hypoglycemia: CRC(At 0-240 minutes following administration of study drug)
- Incidence of serious hypoglycemia: CRC(At 0-240 minutes following administration of study drug)
- Incidence of serious hypoglycemia: Out-patient(During 12 weeks of out-patient treatment)
- Hypoglycemia Fear Scale(During 12 weeks of out-patient treatment)
- EuroQol Health Questionnaire (EQ-5D)(During 12 weeks of out-patient treatment)
研究者
研究点 (5)
Loading locations...
相似试验
终止
2 期
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary GeneralizationRefractory EpilepsyNCT04153175Cerebral Therapeutics LLC30
已完成
2 期
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaSarcopeniaLiver CirrhosisNCT04874350Lipocine Inc.30
已完成
2 期
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)Hypertension, PulmonaryNCT04945460Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA164
已完成
2 期
Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower ExtremitiesDiabetic FootNCT00493051Tissue Repair Company124
已完成
2 期
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate TherapyRheumatoid ArthritisNCT01242917Amgen159